Aclaris Therapeutics (ACRS) Expected to Post Quarterly Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.16) per share and revenue of $1.27 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.38 million. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. On average, analysts expect Aclaris Therapeutics to post ($0.62) EPS for the current fiscal year and ($0.63) EPS for the next fiscal year.

Aclaris Therapeutics Stock Up 1.2%

Aclaris Therapeutics stock traded up $0.04 during trading hours on Tuesday, hitting $3.85. The stock had a trading volume of 176,660 shares, compared to its average volume of 2,216,749. The stock has a market capitalization of $537.61 million, a P/E ratio of -6.64 and a beta of 0.87. Aclaris Therapeutics has a 12-month low of $2.10 and a 12-month high of $6.60. The stock’s 50-day moving average price is $4.83 and its 200-day moving average price is $4.52.

Analysts Set New Price Targets

ACRS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Wedbush decreased their price objective on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Canaccord Genuity Group increased their target price on Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a research note on Friday. Finally, Craig Hallum set a $9.00 target price on Aclaris Therapeutics in a report on Wednesday, October 28th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Aclaris Therapeutics has a consensus rating of “Buy” and a consensus target price of $11.33.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.